Online citations, reference lists, and bibliographies.
← Back to Search

Retreatment With Pemetrexed-based Chemotherapy In Malignant Pleural Mesothelioma (MPM): A Second Line Treatment Option.

A. Razak, Katy J Chatten, A. Hughes
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
The role of second line treatment in malignant pleural mesothelioma (MPM) is currently undefined. We present four cases of patients who had durable responses from pemetrexed-based chemotherapy who were retreated with a similar regimen upon progression of their mesothelioma. This case series explores the possible role of retreatment with pemetrexed-based chemotherapy as a second line therapeutic option in MPM.
This paper references

This paper is referenced by
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin
J. Delourme (2013)
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Wei-Sen Lam (2019)
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma
Letizia Gianoncelli (2019)
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
Miliary mesothelioma: a new clinical and radiological presentation in mesothelioma patients with prolonged survival after trimodality therapy.
L. Purek (2011)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
Systemic treatment of malignant pleural mesothelioma.
F. Grosso (2012)
Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
Marjorie G Zauderer (2017)
The Role of Immunotherapy in Malignant Mesothelioma
Kastelik Ja (2018)
Association pemetrexed–cisplatine en première ligne dans le mésothéliome pleural malin non opérable
Markus Burgin (2009)
Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed
Hidetoshi Hayashi (2010)
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma
Paolo Andrea Zucali (2010)
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
Chemotherapy and radiotherapy for mesothelioma.
Xavier Dhalluin (2011)
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
H. Uramoto (2010)
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
G. Pasello (2011)
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.
C. Pinto (2013)
Sarcomatoid Mesothelioma: Future Advances in Diagnosis, Biomolecular Assessment, and Therapeutic Options in a Poor-Outcome Disease
Domenico Galetta (2016)
Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
J. Steer (2010)
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
Semantic Scholar Logo Some data provided by SemanticScholar